Fortrea Holdings Inc.
About Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.7B
- Net income
- -$986.2M
- Total assets
- $2.7B
- Market cap
- $1.5B
- Operating margin
- -32.0%
- Net margin
- -36.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.7B
- Operating expenses
- $3.6B
- Operating income
- -$872.6M
- Income tax
- $3.2M
- Net income
- -$986.2M
- EPS (basic)
- $-10.81
- EPS (diluted)
- $-10.81
Balance sheet
- Total assets
- $2.7B
- Current assets
- $897.2M
- Total liabilities
- $2.2B
- Current liabilities
- $913.3M
- Shareholders’ equity
- $563.5M
Cash flow
- Operating cash flow
- $113.5M
- Investing cash flow
- $14.4M
- Financing cash flow
- -$76.3M
- Net cash flow
- $56.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.5B
- EPS (diluted)
- $-10.81
- Shares outstanding
- 91.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 16, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $986.2M in FY2025.
- Revenue declined 12% from FY2023 to FY2025.
- Trading 10% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Fortrea Holdings Inc..
Write a review
News about Fortrea Holdings Inc.
News & sentiment via Polygon.io
